Company news
Faron Pharmaceuticals Oy (LSE:FARN) news
Faron Pharmaceuticals Oy news releases on 6ix. Latest, Oct 24, 2016: First patient recruited in Japanese Ph III trial
Press releases — page 9
First patient recruited in Japanese Ph III trial
October 24, 2016
Director Dealing
September 26, 2016
Raises £8.0 M through a Placing and Subscription
September 21, 2016
Proposed Placing & Subscription to raise £8M
September 20, 2016
Interim Results for six months ended 30 June 2016
September 5, 2016
Faron Pharmaceuticals Notice of Interim Results
August 10, 2016
Faron enters agreement with Abzena for Clevegen
July 25, 2016
Faron to Present at Proactive Investors Forum
June 22, 2016
Faron Provides Update at R&D Day
June 14, 2016
Faron Licenses Traumakine Rights to Pharmbio Korea
June 13, 2016
Faron Result of Annual General Meeting
May 26, 2016
Faron Pharmaceuticals Ltd to host an R&D Day
May 13, 2016
Faron Appoints New Medical Director
May 3, 2016
Faron Appoints Panmure Gordon as Joint Broker
April 22, 2016
Faron Files Two New Patents to Protect Clevegen
April 19, 2016
Annual Results for the year ended 31 December 2015
March 10, 2016
Faron files patent application for Traumakine
March 1, 2016
Notice of Preliminary Results
February 10, 2016
Top-line results from Japanese study of Traumakine
January 7, 2016
First Patient recruited in Phase III ARDS Study
December 29, 2015
Faron Awarded ?1.5 million Tekes Funding
December 21, 2015
Key Publication in Journal of Immunology
November 30, 2015
Admission to AIM and first day of dealings
November 17, 2015